Self-administration of chemotherapy at home for myeloma patients
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
This study tests if myeloma patients can safely give themselves chemotherapy injections at home instead of going to the hospital.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AHS Cancer Control Alberta Academic / other |
| Drugs / interventions | Chemotherapy, methotrexate |
| Locations | 2 sites (Calgary, Alberta and 1 other locations) |
| Trial ID | NCT04268199 on ClinicalTrials.gov |
What this trial studies
This study explores the feasibility and safety of patients or caregivers administering subcutaneous bortezomib injections at home for the treatment of symptomatic myeloma. By challenging the traditional hospital-based model of chemotherapy delivery, the study aims to assess whether this approach can maintain efficacy while improving patient convenience and reducing healthcare system burdens. Participants will be monitored through standard care procedures to ensure safety and effectiveness. The study is designed to provide insights into the potential for home-based chemotherapy administration in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with symptomatic myeloma who have previously received bortezomib injections in a clinical setting.
Not a fit: Patients with a history of severe allergic reactions to bortezomib or those currently participating in other bortezomib-related clinical trials may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance patient autonomy and comfort while maintaining effective treatment for myeloma.
How similar studies have performed: Other studies have shown success with home administration of similar therapies, indicating potential for this approach to be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma, * Stable clinical status as deemed by responsible investigator, * Personally (or caregiver) willing and deemed capable to self-administer with teaching, * Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment, * Signed informed consent. Exclusion Criteria: * Currently participating in clinical trials that includes the use of bortezomib, * History of allergic reactions to bortezomib, * History of bleeding attributable to bortezomib, * History of greater than or equal to grade 3 side effects attributable to bortezomib, * Clinically deemed unlikely to be compliant with therapy by responsible investigator, * Life expectancy anticipated to be less than 6 months, * Deemed geographically inaccessible to receive care.
Where this trial is running
Calgary, Alberta and 1 other locations
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (Recruiting)
- Cross Cancer Institute — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Jason Tay, MD — Arthur J.E. Child Comprehensive Cancer Centre
- Study coordinator: Jason Tay, MD
- Email: Jason.Tay@ahs.ca
- Phone: 587-231-5437
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.